CytoSorb Reduction of Free Hemoglobin During Cardiac Surgery (REFRESH)
CytoSorb Reduction of Free Hemoglobin During Cardiac Surgery
To assess the impact of the CytoSorb device during cardiopulmonary bypass compared to standard of care without CytoSorb. Measures include change in plasma free hemoglobin; assessment of device-related adverse events; time on ventilator; time in ICU; hospital stay; incidence of acute kidney injury; and others.
Are you Eligible? (Inclusion Criteria)
Elective, cardiac surgery requiring cardiopulmonary bypass with anticipated duration of >180 minutes